Press Release

November 04, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Press Release on Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2026 Dear Sir/ Madam, Please find enclosed herewith the Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2026. We request you to please take the same on record. Thanking You, Yours Faithfully, For Dr. Lal PathLabs Limited Vinay Gujral Company Secretary & Compliance Officer Encl.: As above Classification: Internal For Immediate Release November 4, 2026 Dr Lal PathLabs Limited records revenue of Rs 874 Cr with a growth of 19.6% in Q2 FY27 New Delhi, India, November 4, 2026 – Dr Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended September 30, 2026. Consolidated Performance Highlights: Q2 FY27 • Revenue increased by 19.6% in Q2 FY27 and 19.4% in H1 FY27. • EBITDA for Q2 FY27 increased by 25.1% with a margin of 32.1% • EBITDA for H1 FY27 increased by 26.7% with a margin of 31.6% • PAT for Q2 FY27 is Rs 194 Cr. increased by 27.5% with a margin for of 22.2% • PAT for H1 FY27 is Rs 364 Cr. increased by 27.3% with a margin for of 21.8% • Interim Dividend of 50% i.e. Rs. 5 per share. • Cash and Cash equivalents as on 30th September 2026 is Rs. 1,746 Cr. Financial Overview (Consolidated) in Rs Cr Q2 FH Particulars FY27 FY26 Gr % FY27 FY26 Gr % Revenue 874 731 19.6% 1,672 1,400 19.4% Material consumed 162 142 314 271 Employee benefit Expenses 139 124 271 248 Fees to collection centres 129 109 245 204 Other Expenses 164 132 314 261 Total Expenses 594 507 17.2% 1,144 984 16.3% EBITDA 280 224 25.1% 528 416 26.7% Margins 32.1% 30.7% 31.6% 29.7% Other Income 34 25 66 53 Depreciation Cost 47 41 91 75 Finance Cost 7 5 13 9 PBT 261 204 28.1% 489 385 27.2% Margins 29.8% 27.9% 29.3% 27.5% Income Tax 67 51 125 98 PAT 194 152 27.5% 364 286 27.3% Margins 22.2% 20.8% 21.8% 20.4% EPS 11.5 9.0 27.5% 21.7 17.0 27.6% Dr Lal Pathlabs Limited 12th Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com 1 About Dr Lal PathLabs Limited Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its’ integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. As on March 31, 2026 the company has 312 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 7,727 Patient Service Centers (PSCs) and 13,935 Pick-up Points (PUPs). Its’ customers include individual patients, hospitals and other healthcare providers and corporate customers. Contact Details Ved Goel Group Chief Financial Officer & +91 124 3016500 CEO- International Business cfo@lalpathlabs.com Dr Lal PathLabs Limited +91 8604801332 Kritika Khatwani kritika.khatwani@adfactorspr.com Adfactors PR For further information on Dr Lal PathLabs see www.lalpathlabs.com Safe Harbour This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances. Dr Lal Pathlabs Limited 12th Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com 2